CLAIMS

1. Use of pentosan polysulfate or an acceptable salt thereof, in the manufacture of a medicament for treating malignant bone pain mediated by Nerve Growth Factor (NGF) or pro-Nerve Growth Factor (pro-NGF) activity in a mammal, wherein the medicament is to be administered by intra-muscular (IM) or sub-cutaneous (SC) routes, an intraventricular route, intracisternal route or intrathecal route, intra-venously (IV), intra-articularly (IA), peri-articularly, topically or via suppositories.

2. The use according to claim 1, wherein the pentosan polysulfate (PPS) is selected from the group consisting of: the sodium salt of pentosan polysulfate (NaPPS), the magnesium salt of pentosan polysulfate (MgPPS), the calcium salt of pentosan polysulfate (CaPPS), and the zinc salt of pentosan polysulfate (ZnPPS).

3. The use according to Claim 1 or Claim 2, wherein the pentosan polysulfate (PPS) is sodium pentosan polysulfate (NaPPS).

4. The use according to any one of claims 1 to 3, wherein the pentosan polysulfate or the acceptable salt thereof is to be administered to the mammal in an effective amount of about 1 mg/kg to about 2 mg/kg of the mammal per dose.

5. The use according to claim 4, wherein the composition is to be dosed to the mammal once daily, twice weekly or thrice weekly.

6. The use according to claim 5, wherein the total dose of pentosan polysulfate to be administered is about 200 to 4000 mg.

7. The use according to any one of claims 1 to 3, wherein the pentosan polysulfate or the acceptable salt thereof is to be administered to the mammal in an effective amount in the range of about 10 ng to about 1000 ng.

8. The use according to any one of claims 1 to 3, wherein the pentosan polysulfate or the acceptable salt thereof is to be administered to the mammal in an effective amount in the range of about 1 mg to about 25 mg.